GlucoTrack, Inc. (IGAP)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GlucoTrack, Inc. (IGAP) trades at $3.24. GlucoTrack, Inc. develops and commercializes non-invasive glucose monitoring devices for individuals with diabetes and pre-diabetes. Their GlucoTrack device aims to provide pain-free blood glucose level readings. Market cap: $50.23M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for IGAP: IGAP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IGAP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IGAP: 1/1 perspectives are bearish.
How is this calculated? →GlucoTrack, Inc. (IGAP) Healthcare & Pipeline Overview
GlucoTrack, Inc. focuses on non-invasive glucose monitoring technology, offering an alternative to traditional blood glucose testing methods. The company targets the diabetes and pre-diabetes market in Europe and the Asia Pacific, differentiating itself through its pain-free approach to glucose level readings within the medical devices sector.
What Is the Investment Thesis for IGAP?
GlucoTrack, Inc. presents a compelling investment thesis centered on its innovative non-invasive glucose monitoring technology. The company's potential lies in capturing a segment of the diabetes care market seeking pain-free alternatives to traditional blood glucose monitoring. Key value drivers include successful commercialization and regulatory approvals in target markets, expansion of the GlucoTrack device's capabilities, and strategic partnerships to broaden market reach. A potential catalyst is the expansion of distribution networks within Europe and Asia Pacific. However, investors may want to evaluate risks associated with market adoption of new technologies, competition from established players in the diabetes care market, and the company's current financial position, with a market capitalization of $50.23M and a negative P/E ratio of -0.04.
Based on FMP financials and quantitative analysis
IGAP Key Highlights
- GlucoTrack, Inc. focuses on non-invasive glucose monitoring technology.
- The company targets the diabetes and pre-diabetes market in Europe and the Asia Pacific.
- GlucoTrack's device aims to provide pain-free blood glucose level readings.
- The company has a market capitalization of $50.23M.
- GlucoTrack operates with a team of 11 employees.
Who Are IGAP's Competitors?
IGAP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AHG Akso Health Group | $1.51 | -0.66% | $143.04M | 67 |
| AKYA Akoya Biosciences, Inc. | $1.29 | -5.15% | $64.44M | 50 |
| ALR AlerisLife Inc. | $1.32 | +0.00% | $44.18M | 39 |
| ALVR AlloVir, Inc. | $9.81 | +4.14% | $49.48M | 46 |
| BLUE bluebird bio, Inc. | $4.97 | +0.00% | $48.67M | 67 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IGAP's Key Strengths?
- Proprietary non-invasive glucose monitoring technology.
- Potential to improve patient compliance with glucose monitoring.
- Targets a growing market with increasing prevalence of diabetes.
What Are IGAP's Weaknesses?
- Limited market presence and brand recognition.
- Reliance on a single product (GlucoTrack).
- Small team size and limited resources.
What Could Drive IGAP Stock Higher?
- Potential regulatory approvals in new geographic markets.
- Continued commercialization efforts in Europe and the Asia Pacific.
- Development and enhancement of the GlucoTrack device.
What Are the Key Risks for IGAP?
- Financial-distress signal — its Altman Z-Score of -44.61 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established players in the diabetes care market.
- Regulatory hurdles and approval processes.
- Risk of technological obsolescence.
- Limited market presence and brand recognition.
What Are the Growth Opportunities for IGAP?
- Expansion into New Geographic Markets: GlucoTrack has the opportunity to expand its market presence beyond Europe and the Asia Pacific region. Entering the North American market, with its large diabetic population, could significantly increase revenue. This expansion would require regulatory approvals from the FDA and strategic partnerships with distributors. The global market for diabetes care devices is expected to reach $30 billion by 2028, providing a substantial opportunity for GlucoTrack to capture market share through geographic expansion. Timeline: 2-3 years for regulatory approvals and market entry.
- Development of Next-Generation Non-Invasive Technology: GlucoTrack can invest in research and development to enhance its non-invasive glucose monitoring technology. Improving the accuracy, reliability, and user-friendliness of the GlucoTrack device could attract a wider customer base and increase market adoption. The company could explore integrating its technology with mobile health platforms and wearable devices. Continuous innovation in non-invasive glucose monitoring is crucial for maintaining a competitive edge in the rapidly evolving diabetes care market. Timeline: Ongoing research and development efforts with incremental improvements every 12-18 months.
- Strategic Partnerships with Healthcare Providers and Insurers: GlucoTrack can establish strategic partnerships with healthcare providers and insurance companies to promote the adoption of its non-invasive glucose monitoring device. Collaborating with healthcare providers can facilitate the integration of GlucoTrack into diabetes management programs. Partnering with insurance companies can improve patient access to the device through reimbursement coverage. These partnerships can enhance GlucoTrack's credibility and market reach. Timeline: Initiate partnerships within the next year and expand over the following 2-3 years.
- Targeting the Pre-Diabetes Market: GlucoTrack can expand its target market to include individuals with pre-diabetes. Early detection and management of pre-diabetes can help prevent the onset of type 2 diabetes. GlucoTrack's non-invasive glucose monitoring device can be used for regular screening and monitoring of individuals at risk of developing diabetes. Educating healthcare providers and the public about the benefits of non-invasive monitoring for pre-diabetes can drive market adoption. The pre-diabetes market represents a significant growth opportunity for GlucoTrack. Timeline: Launch targeted marketing campaigns within the next 6-12 months.
- Integration with Telehealth Platforms: GlucoTrack can integrate its glucose monitoring device with telehealth platforms to provide remote diabetes management services. This integration would allow patients to share their glucose readings with healthcare providers remotely, enabling timely intervention and personalized care. Telehealth platforms are becoming increasingly popular, offering a convenient and cost-effective way to manage chronic conditions like diabetes. GlucoTrack's integration with telehealth platforms can enhance patient engagement and improve health outcomes. Timeline: Develop and launch telehealth integration within the next 18-24 months.
What Opportunities Does IGAP Have?
- Expansion into new geographic markets.
- Development of next-generation non-invasive technology.
- Strategic partnerships with healthcare providers and insurers.
What Threats Does IGAP Face?
- Competition from established players in the diabetes care market.
- Regulatory hurdles and approval processes.
- Risk of technological obsolescence.
What Are IGAP's Competitive Advantages?
- Proprietary non-invasive glucose monitoring technology.
- Patents protecting the GlucoTrack device and its underlying technology.
- First-mover advantage in the non-invasive glucose monitoring market.
What Does IGAP Do?
GlucoTrack, Inc., formerly known as Integrity Applications, Inc., was founded in 2001 and is headquartered in Or Yehuda, Israel. The company specializes in the design, development, and commercialization of non-invasive glucose monitoring devices. Its flagship product, the GlucoTrack device, is intended for use by individuals with diabetes and pre-diabetes, providing a method to obtain blood glucose level readings without the need for painful finger pricks. The company changed its name to GlucoTrack, Inc. in November 2021, reflecting its focus on glucose monitoring solutions. GlucoTrack aims to improve the quality of life for people managing diabetes by offering a more convenient and less invasive monitoring option. The company currently targets markets in Europe and the Asia Pacific region, seeking to establish its presence in the global diabetes care market. GlucoTrack's competitive positioning centers on its unique non-invasive technology, which differentiates it from traditional blood glucose meters and continuous glucose monitoring (CGM) systems that require skin penetration.
What Products and Services Does IGAP Offer?
- Designs non-invasive glucose monitoring devices.
- Develops technology for pain-free blood glucose level readings.
- Commercializes glucose monitoring devices for people with diabetes and pre-diabetes.
- Offers an alternative to traditional blood glucose meters.
- Targets markets in Europe and the Asia Pacific.
- Aims to improve the quality of life for people managing diabetes.
How Does IGAP Make Money?
- Sells GlucoTrack devices to individuals with diabetes and pre-diabetes.
- Generates revenue through device sales and potential subscription-based services.
- Partners with distributors to reach target markets in Europe and the Asia Pacific.
What Industry Does IGAP Operate In?
GlucoTrack, Inc. operates within the medical devices industry, specifically in the diabetes care market. This market is characterized by increasing prevalence of diabetes globally and a growing demand for advanced glucose monitoring solutions. The competitive landscape includes established players offering traditional blood glucose meters and continuous glucose monitoring systems. GlucoTrack aims to differentiate itself through its non-invasive technology, targeting a niche market seeking pain-free monitoring options. The global diabetes care devices market is projected to reach significant growth in the coming years, driven by technological advancements and increasing awareness of diabetes management.
Who Are IGAP's Key Customers?
- Individuals with diabetes.
- Individuals with pre-diabetes.
- Healthcare providers involved in diabetes management.
F-Score 2/9Financial Health
GlucoTrack, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -44.61 places it in the distress zone, a signal of elevated financial risk.
GlucoTrack, Inc. (IGAP) Valuation Context
Valued at $50.23M, IGAP is classified as a micro-cap stock.
Company Profile
GlucoTrack, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Ashdod, IL. The company is led by CEO David Malka. IGAP has traded publicly since 2013.
IGAP Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in GlucoTrack's growth potential, indicating that those closest to the company believe in its future.
- Community sentiment has shifted positively, with discussions highlighting the innovative technology behind GlucoTrack's non-invasive glucose monitoring.
- Increased media coverage has raised awareness of the product, leading to a growing interest from potential customers and investors alike.
- Recent partnerships with healthcare providers could enhance distribution channels, positioning GlucoTrack favorably in the competitive market.
Bear Case
- Concerns about regulatory hurdles remain prevalent, as the medical device industry often faces lengthy approval processes that could delay product rollout.
- Despite positive sentiment, some community members express skepticism regarding the scalability of GlucoTrack's technology in diverse populations.
- Recent market developments indicate heightened competition from established players in the glucose monitoring space, which could impact market share.
- The company has not yet demonstrated consistent revenue growth, leading to doubts about its financial sustainability in the long term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IGAP Latest News
No recent news available for IGAP.
IGAP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IGAP.
Price Targets
Wall Street price target analysis for IGAP.
IGAP MoonshotScore
What does this score mean?
The MoonshotScore rates IGAP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David Malka
CEO
David Malka serves as the CEO of GlucoTrack, Inc. His background includes experience in managing and leading teams, as evidenced by his current role overseeing 11 employees. Additional details regarding his specific career history, educational background, and previous roles are not available in the provided data.
Track Record: Information regarding David Malka's specific achievements, strategic decisions, and company milestones under his leadership at GlucoTrack, Inc. is not available in the provided data.
GlucoTrack, Inc. Healthcare Stock: Key Questions Answered
What does GlucoTrack, Inc. do?
GlucoTrack, Inc. is a medical device company focused on designing, developing, and commercializing non-invasive glucose monitoring devices. Their primary product, the GlucoTrack device, aims to provide a pain-free alternative to traditional blood glucose meters for individuals with diabetes and pre-diabetes. The company targets markets in Europe and the Asia Pacific, seeking to establish itself as a leader in non-invasive glucose monitoring technology. GlucoTrack's business model revolves around selling its devices and potentially offering subscription-based services for ongoing monitoring and data analysis.
What are the main risks for IGAP?
The main risks for GlucoTrack, Inc. include competition from established players in the diabetes care market, regulatory hurdles and approval processes, and the risk of technological obsolescence. The company faces competition from companies offering traditional blood glucose meters and continuous glucose monitoring systems. Securing regulatory approvals in new markets can be a lengthy and costly process. Additionally, the company must continuously innovate to maintain a competitive edge in the rapidly evolving field of glucose monitoring technology. Limited market presence and brand recognition also pose challenges for GlucoTrack.
What are the key growth opportunities for IGAP in healthcare?
GlucoTrack, Inc.'s key growth opportunities in healthcare lie in expanding its market presence beyond Europe and the Asia Pacific, developing next-generation non-invasive technology, and establishing strategic partnerships with healthcare providers and insurers. The company can also target the pre-diabetes market and integrate its glucose monitoring device with telehealth platforms. These opportunities would allow GlucoTrack to increase revenue, improve patient access to its device, and enhance its competitive positioning in the diabetes care market. Successful execution of these growth strategies is crucial for the company's long-term success.
How does GlucoTrack, Inc.'s non-invasive technology differentiate it from competitors in the diabetes monitoring market?
GlucoTrack, Inc.'s non-invasive technology differentiates it from competitors by offering a pain-free alternative to traditional blood glucose monitoring methods. Unlike traditional blood glucose meters and continuous glucose monitoring (CGM) systems that require skin penetration, GlucoTrack's device aims to provide blood glucose level readings without the need for finger pricks. This non-invasive approach can improve patient compliance with glucose monitoring and enhance the overall user experience. The company's proprietary technology and patents provide a competitive advantage in the non-invasive glucose monitoring market.
What are the key factors to evaluate for IGAP?
Evaluate IGAP on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does IGAP data refresh on this page?
IGAP prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IGAP's recent stock price performance?
GlucoTrack, Inc. (IGAP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary non-invasive glucose monitoring technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IGAP overvalued or undervalued right now?
Valuing GlucoTrack, Inc. (IGAP) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for IGAP.
- Limited financial data available.